NYSE:MED Medifast - MED Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $97.09 -2.01 (-2.03%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$97.09▼$99.7250-Day Range$97.09▼$119.6852-Week Range$96.00▼$197.19Volume176,947 shsAverage Volume199,606 shsMarket Capitalization$1.05 billionP/E Ratio7.65Dividend Yield6.76%Price Target$122.00 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Medifast MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside25.7% Upside$122.00 Price TargetShort InterestBearish14.38% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-2.06Upright™ Environmental ScoreNews Sentiment0.60Based on 4 Articles This WeekInsider TradingSelling Shares$239,096 Sold Last QuarterProj. Earnings Growth6.72%From $10.72 to $11.44 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.65 out of 5 starsConsumer Staples Sector47th out of 138 stocksMiscellaneous Food Preparations & Kindred Products Industry2nd out of 5 stocks 3.0 Analyst's Opinion Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $122.00, Medifast has a forecasted upside of 25.7% from its current price of $97.09.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.38% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Medifast has recently decreased by 1.29%, indicating that investor sentiment is improving. Previous Next 3.3 Dividend Strength Dividend LeadershipMedifast is a leading dividend payer. It pays a dividend yield of 6.74%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthMedifast has only been increasing its dividend for 3 years.Dividend CoverageThe dividend payout ratio of Medifast is 51.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Medifast will have a dividend payout ratio of 57.34% next year. This indicates that Medifast will be able to sustain or increase its dividend. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedifast has received a 29.01% net impact score from Upright. The largest positive contribution comes from its "Nutrition" impact, which is mostly driven by its "Meal replacement drinks", "Granola without added sugar", and "Protein shakes" products. See details.Environmental SustainabilityThe Environmental Impact score for Medifast is -2.06. Previous Next 2.0 News and Social Media Coverage News SentimentMedifast has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Medifast this week, compared to 4 articles on an average week.Search InterestOnly 44 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of -62% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have sold 253.89% more of their company's stock than they have bought. Specifically, they have bought $67,563.00 in company stock and sold $239,096.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of Medifast is held by insiders.Percentage Held by Institutions86.03% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Medifast are expected to grow by 6.72% in the coming year, from $10.72 to $11.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 7.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 7.65, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 22.20.Price to Book Value per Share RatioMedifast has a P/B Ratio of 6.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Medifast (NYSE:MED) StockMedifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.Read More Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Stock News HeadlinesMarch 26, 2023 | americanbankingnews.comMedifast, Inc. (NYSE:MED) to Issue Dividend Increase - $1.65 Per ShareMarch 23, 2023 | finance.yahoo.comMedifast (MED) Down 2.7% Since Last Earnings Report: Can It Rebound?March 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 15, 2023 | marketwatch.comNutrition & Weight Management Market Size, Growth | Soaring Demand | 2023 - 2029March 10, 2023 | marketwatch.com2023 Nutrition & Weight Management Market Size Forecast 2029: Global Leaders' Sales and Profit Analysis for Business GrowthMarch 2, 2023 | finance.yahoo.comMedifast Appoints Steven Zenker as Vice President of Investor RelationsFebruary 26, 2023 | finance.yahoo.comOne Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's EstimatesFebruary 22, 2023 | finance.yahoo.comMedifast's Q4 revenue declines as CEO predicts losses will continue in 2023March 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 22, 2023 | finance.yahoo.comMedifast (MED) Stock Down Despite Q4 Earnings, Sales BeatFebruary 21, 2023 | finance.yahoo.comMedifast Announces Fourth Quarter and Full Year 2022 Financial ResultsFebruary 13, 2023 | marketwatch.comOrganic Breakfast Cereals Market Outlook 2023 and Forecast to 2028 with Top Countries DataFebruary 13, 2023 | marketwatch.comMeal Replacement Products Market Players to drive Merges and Acquisition Strategies to Expand Market Share, 2023-2027February 7, 2023 | finance.yahoo.comMedifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022February 2, 2023 | finance.yahoo.comPost Holdings (POST) Surpasses Q1 Earnings and Revenue EstimatesJanuary 24, 2023 | marketwatch.comWeight Loss Diet Market Players to drive Merges and Acquisition Strategies to Expand Market Share, 2023-2027January 4, 2023 | finance.yahoo.comEstimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)January 3, 2023 | msn.comOptavia Diet Review: Everything You Need to KnowDecember 30, 2022 | finance.yahoo.comMedifast (MED) Banks on OPTAVIA Strength Amid Cost WoesDecember 28, 2022 | finance.yahoo.com7 Ridiculously Cheap Stocks Yielding 5% in 2023December 14, 2022 | finance.yahoo.com15 Biggest Diet/Weight Loss Companies in the WorldDecember 9, 2022 | seekingalpha.comMedifast Stock Shows Promise At Current ValuationDecember 5, 2022 | finance.yahoo.comMedifast Survey Indicates Consumer Focus on Health and Wellbeing Remains StrongNovember 26, 2022 | marketwatch.comWeight Loss and Diet Management Market Size And Opportunities for New Players, Forecast from 2022 To 2028 with Top Countries DataNovember 26, 2022 | marketwatch.comWeight Loss Services Market 2023 : Trend Analysis, Competitive Outlook of Top Industry Players and Future Expansion by 2028November 22, 2022 | msn.comMedifast's Return on Invested Capital InsightsNovember 16, 2022 | finance.yahoo.comMedifast Named to the 2022 FORTUNE 100 Fastest-Growing Companies ListSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Company Calendar Last Earnings11/04/2021Ex-Dividend for 2/7 Dividend12/19/2022Dividend Payable2/07/2023Ex-Dividend for 5/9 Dividend3/27/2023Today3/28/2023Next Earnings (Estimated)5/01/2023Dividend Payable5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products SectorConsumer Staples Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees984Year FoundedN/APrice Target and Rating Average Stock Price Forecast$122.00 High Stock Price Forecast$150.00 Low Stock Price Forecast$94.00 Forecasted Upside/Downside+23.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$12.69 Trailing P/E Ratio7.81 Forward P/E Ratio9.24 P/E GrowthN/ANet Income$143.57 million Net Margins8.98% Pretax Margin11.51% Return on Equity100.42% Return on Assets46.55% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio0.74 Sales & Book Value Annual Sales$1.60 billion Price / Sales0.67 Cash Flow$16.25 per share Price / Cash Flow6.10 Book Value$14.19 per share Price / Book6.98Miscellaneous Outstanding Shares10,850,000Free Float10,596,000Market Cap$1.08 billion OptionableOptionable Beta1.16 Key ExecutivesDaniel R. ChardExecutive Chairman & Chief Executive OfficerAnthony TyreeChief Business Operations OfficerJames P. MaloneyChief Financial OfficerNicholas M. JohnsonChief Field Operations OfficerLauren WalkerExecutive Vice President-Supply Chain OperationsKey CompetitorsUtz BrandsNYSE:UTZJohn B. Sanfilippo & SonNASDAQ:JBSSMatthews InternationalNASDAQ:MATWB&G FoodsNYSE:BGSBRCNYSE:BRCCView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 529 shares on 3/23/2023Ownership: 0.051%Victory Capital Management Inc.Sold 37,603 shares on 3/10/2023Ownership: 0.635%Scott SchlackmanSold 2,200 sharesTotal: $239,096.00 ($108.68/share)Voya Investment Management LLCBought 610 shares on 2/28/2023Ownership: 0.101%Teachers Retirement System of The State of KentuckySold 1,178 shares on 2/22/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions MED Stock - Frequently Asked Questions Should I buy or sell Medifast stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares. View MED analyst ratings or view top-rated stocks. What is Medifast's stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month price objectives for Medifast's shares. Their MED share price forecasts range from $94.00 to $150.00. On average, they predict the company's stock price to reach $122.00 in the next twelve months. This suggests a possible upside of 23.1% from the stock's current price. View analysts price targets for MED or view top-rated stocks among Wall Street analysts. How have MED shares performed in 2023? Medifast's stock was trading at $115.35 at the beginning of the year. Since then, MED shares have decreased by 14.1% and is now trading at $99.10. View the best growth stocks for 2023 here. Are investors shorting Medifast? Medifast saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,550,000 shares, an increase of 31.4% from the February 13th total of 1,180,000 shares. Based on an average daily volume of 173,100 shares, the days-to-cover ratio is presently 9.0 days. Currently, 14.6% of the company's shares are sold short. View Medifast's Short Interest. When is Medifast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023. View our MED earnings forecast. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) posted its quarterly earnings data on Thursday, November, 4th. The specialty retailer reported $3.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.92 by $0.64. The specialty retailer had revenue of $413.40 million for the quarter, compared to the consensus estimate of $402.80 million. Medifast had a trailing twelve-month return on equity of 100.42% and a net margin of 8.98%. The business's quarterly revenue was up 52.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.91 EPS. How often does Medifast pay dividends? What is the dividend yield for Medifast? Medifast announced a quarterly dividend on Thursday, March 16th. Stockholders of record on Tuesday, March 28th will be given a dividend of $1.65 per share on Tuesday, May 9th. This represents a $6.60 dividend on an annualized basis and a yield of 6.66%. The ex-dividend date is Monday, March 27th. This is a boost from the stock's previous quarterly dividend of $1.64. Read our dividend analysis for MED. What ETFs hold Medifast's stock? ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), Inspire Fidelis Multi Factor ETF (FDLS), First Trust SMID Cap Rising Dividend Archievers ETF (SDVY), Roundhill Acquirers Deep Value ETF (DEEP), Pacer US Small Cap Cash Cows 100 ETF (CALF), VictoryShares US Small Cap High Div Volatility Wtd ETF (CSB), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS) and Invesco S&P SmallCap Quality ETF (XSHQ). Is Medifast a good dividend stock? Medifast (NYSE:MED) pays an annual dividend of $6.56 per share and currently has a dividend yield of 6.74%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 51.69%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MED will have a dividend payout ratio of 57.34% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for MED. What guidance has Medifast issued on next quarter's earnings? Medifast updated its first quarter 2023 earnings guidance on Tuesday, February, 21st. The company provided earnings per share (EPS) guidance of $1.75-$2.40 for the period, compared to the consensus estimate of $3.26. The company issued revenue guidance of $300.00 million-$320.00 million, compared to the consensus revenue estimate of $374.30 million. What is Daniel Chard's approval rating as Medifast's CEO? 44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM). What is Medifast's stock symbol? Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED." Who are Medifast's major shareholders? Medifast's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.78%), Dimensional Fund Advisors LP (3.07%), Morgan Stanley (2.66%), Rice Hall James & Associates LLC (2.46%), Principal Financial Group Inc. (2.12%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Medifast's stock price today? One share of MED stock can currently be purchased for approximately $99.10. How much money does Medifast make? Medifast (NYSE:MED) has a market capitalization of $1.08 billion and generates $1.60 billion in revenue each year. The specialty retailer earns $143.57 million in net income (profit) each year or $12.69 on an earnings per share basis. How many employees does Medifast have? The company employs 984 workers across the globe. How can I contact Medifast? Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070. This page (NYSE:MED) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.